Because during treatment with antiplatelet agents the balance between the risk of thrombosis resulting in recurrent cardiovascular events and the risk of bleeding is important, the impact of PON1 genetic polymorphism on the clinical outcome in the form of MACE or bleeding occurrence was evaluated in patients with CHD after percutaneus coronary intervention PCI. This evidence concerns the gene PON1 and coronary artery disorder.